查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2154058

抗甲狀腺藥物市場：全球市場預測，2026-2032年

Antithyroid Preparations Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗甲狀腺藥物市場規模將達到 25.7 億美元，年複合成長率為 5.31%。

主要市場統計數據
基準年 2025 17.8億美元
預計年份：2026年 18.6億美元
預測年份 2032 25.7億美元
複合年成長率 (%) 5.31%

抗甲狀腺藥物：概述

抗甲狀腺藥物主要用於治療甲狀腺亢進和格雷夫茲病，以抑制甲狀腺激素的產生。臨床用藥選擇取決於疾病的嚴重程度、病患年齡、懷孕狀態、肝功能、共病、治療目標、以及當地的用藥指引。常見的治療方法包括硫脲類藥物、放射性碘治療和手術，但這些治療方案在作用機制、監測要求、禁忌症以及對不同患者的適用性方面存在差異。

治療方案正變得越來越個人化。

治療方法正從統一用藥轉向以風險為基礎的治療。臨床醫生越來越重視緩解的可能性、不利事件的風險、妊娠注意事項、根治性治療的意願以及長期生化監測的必要性。由於抗甲狀腺藥物可能引起具有臨床意義的反應，例如粒細胞缺乏症和肝毒性，因此安全監測仍然至關重要。所以，對患者進行清晰的預警訊號教育和快速的實驗室評估對於合理用藥至關重要。

人工智慧驅動的監測和臨床決策支持

人工智慧 (AI) 可以透過識別需要進行甲狀腺功能檢測的患者、突出藥物相關風險模式、輔助解讀連續檢測結果以及幫助確定追蹤優先級，從而最佳化抗甲狀腺藥物治療的工作流程。當與電子健康記錄、藥房數據、臨床指南和患者自述症狀相結合時，其價值將得到協同增強。然而，由於治療決策需要結合具體情況進行判斷、檢驗的證據、保護患者隱私以及謹慎管理演算法偏差，因此人工監督仍然至關重要。

區域洞察：在醫療服務取得、監測和醫療服務提供方面觀察到的差異。

在北美，以指南為基礎的管理、透過檢測進行監測以及以患者為中心的決策普遍受到重視；而在拉丁美洲，醫療服務的可及性各不相同，專科醫生的可及性也存在差異。在歐洲，成熟的臨床指引與各國特有的保險報銷和處方制度結合。中東的特點是專科醫生網路不斷擴展、轉診模式多樣化以及醫療體系的多元化。在非洲，部分地區在診斷、檢測和藥物取得方面仍有限制。在亞太地區，高度發展的醫療體系與快速擴張的醫療網路並存，因此，醫療服務提供者的可近性、成本效益和持續監測成為關鍵優先事項。

群體洞察：區域集團塑造標準與准入

東協市場在醫療保健資金、專科醫生資源和監管實施方面存在顯著差異。金磚國家成員國在生產能力、公共採購、診斷基礎設施和治療路徑方面也存在顯著差異。歐盟雖然受益於通用的監管原則，但在報銷制度和服務提供方面仍存在國家差異。七國集團（G7）的醫療保健系統通常擁有完善的臨床基礎設施和藥物安全監測系統，但成本效益和醫療協調仍然是關鍵挑戰。海灣合作理事會（GCC）國家通常將資源豐富的都市區醫療保健服務與以專科醫生為主導的醫療模式相結合，而北約成員國的醫療保健系統和災害應對優先事項各不相同，這影響了醫療供應的韌性和治療的連續性。

各國具體情況：醫療保健系統優先事項的差異

澳洲和加拿大優先在其地域分散的人口中推行基於指南的醫療保健。巴西和墨西哥必須解決專科醫師診療和診斷後追蹤的區域差異。中國和印度面臨巨大的臨床需求，但都市區醫療服務存在差異。法國、德國、義大利、西班牙和英國均遵循既定的歐洲醫療保健框架，但在報銷制度、轉診途徑和處方規範方面存在差異。日本和韓國強調專科醫生監測和系統化的醫療保健服務。俄羅斯的醫療保健格局受國內醫療服務取得、採購和區域服務差異的影響。在美國，除了持續關注成本效益和醫療服務可近性問題外，還高度重視不利事件監測、專科照護和治療方案選擇。

領導階層優先事項：提高安全性、便利性和連續性。

產業領導者應將產品策略與實證治療路徑結合，並提供可操作的工具，用於監測甲狀腺功能、識別不利事件和支持用藥依從性。與臨床醫生、藥房、實驗室和公共衛生系統合作可以改善醫療服務的連續性，尤其是在專科醫生資源有限的地區。數位化和人工智慧驅動的服務應在經過臨床檢驗、透明管治、網路安全措施和人工審核後方可實施。供應計劃應優先考慮品質保證、合規性和跨不同採購管道的韌性。患者教育應使用簡明易懂的語言，並強調如果出現嚴重預警症狀，必須立即就醫。

調查方法：基於證據的市場評估

本執行摘要回顧了已建立的臨床實踐、藥物安全原則、醫療保健系統特徵、監管考慮以及各地區抗甲狀腺藥物的可及性。該評估涵蓋了指定區域、群體和國家的地理範圍，但未使用市場估算、預測、市場規模、市場佔有率、預測結果或公司特定聲明。所有解讀均以定性方式呈現，在實際應用前，應根據現行的國家指南、監管指示、藥物安全監測結果和當地檢驗資訊進行驗證。

結論：安全和情境管理仍然非常重要。

目前抗甲狀腺藥物的特點是：個人化治療、嚴密的安全監測，以及診斷和後續觀察取得的差異。區域和國家間的差異要求實施因地制宜的護理模式，而人工智慧若能得到妥善管理，則可為監測和最佳化營運流程提供有益的支援。永續發展需要實證處方、可靠的診斷、病患教育、穩定的藥物供應，以及臨床醫生、監管機構、醫療衛生系統和社區之間的協作。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：抗甲狀腺藥物市場：依藥物類型分類

  • 卡比馬唑
  • 甲巰咪唑
  • 丙硫氧嘧啶

第8章：抗甲狀腺藥物市場：依產品形式分類

  • 注射藥物
  • 液體
  • 藥片

第9章：抗甲狀腺藥物市場：依產品類型分類

  • 品牌
  • 非專利的

第10章：抗甲狀腺藥物市場：依適應症分類

  • 格雷夫茲病
  • 毒性結節性甲狀腺腫

第11章：抗甲狀腺藥物市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第12章：抗甲狀腺藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：抗甲狀腺藥物市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：抗甲狀腺藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：抗甲狀腺藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Bio-T Ltd.
  • Cadila Healthcare Ltd.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Emcure Pharmaceuticals Ltd.
  • Gland Pharma Ltd.
  • GlaxoSmithKline plc
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Intas Pharmaceuticals Ltd.
  • Ipca Laboratories Ltd.
  • Lannett Company, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis International AG
  • Orion Corporation
  • Pfizer Inc.
  • Piramal Enterprises Ltd.
  • Sanofi SA
  • Strides Pharma Science Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • The Procter & Gamble Company
  • Torrent Pharmaceuticals Ltd.
  • Uni-Sankyo Ltd.
  • Wockhardt Ltd.

第18章 主要專家

Product Code: MRR-537DB9F46DAB

The Antithyroid Preparations Market is projected to grow by USD 2.57 billion at a CAGR of 5.31% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.78 billion
Estimated Year [2026] USD 1.86 billion
Forecast Year [2032] USD 2.57 billion
CAGR (%) 5.31%

Antithyroid Preparations: Executive Overview

Antithyroid preparations are medicines used to reduce thyroid hormone production, primarily in hyperthyroidism and Graves' disease. Clinical selection depends on disease severity, patient age, pregnancy status, liver function, comorbidities, treatment goals, and local prescribing guidance. Common therapeutic approaches include thionamides, radioactive iodine, and surgery, although these options differ in mechanism, monitoring requirements, contraindications, and suitability for individual patients.

Treatment Pathways Are Becoming More Individualized

The treatment landscape is shifting from one-size-fits-all prescribing toward risk-based care. Clinicians increasingly weigh remission prospects, adverse-event risks, pregnancy considerations, definitive-treatment preferences, and the need for long-term biochemical monitoring. Safety surveillance remains central because antithyroid medicines can cause clinically important reactions, including agranulocytosis and hepatotoxicity. Clear patient education about warning symptoms and prompt laboratory assessment is therefore integral to responsible use.

Artificial Intelligence Supports Monitoring and Clinical Decision-Making

Artificial intelligence can strengthen antithyroid-care workflows by identifying patients who may need thyroid-function testing, flagging medication-related risk patterns, supporting interpretation of serial laboratory results, and helping prioritize follow-up. Its value is cumulative when integrated with electronic records, pharmacy data, clinical guidelines, and patient-reported symptoms. Human oversight remains essential because treatment decisions require contextual judgment, validated evidence, privacy safeguards, and careful management of algorithmic bias.

Regional Insights: Access, Monitoring, and Care Delivery Differ

North America generally emphasizes guideline-driven management, laboratory monitoring, and shared decision-making, while Latin America faces uneven access and differences in specialist availability. Europe combines mature clinical guidance with varied national reimbursement and prescribing systems. The Middle East is shaped by expanding specialist capacity, referral patterns, and healthcare-system variation. Africa continues to encounter diagnostic, laboratory, and medicine-access constraints in several settings. Asia-Pacific spans highly developed systems and rapidly expanding care networks, making workforce capacity, affordability, and continuity of monitoring important priorities.

Group Insights: Regional Blocs Shape Standards and Access

ASEAN markets reflect substantial diversity in healthcare financing, specialist access, and regulatory implementation. BRICS members differ widely in manufacturing capacity, public procurement, diagnostic infrastructure, and treatment pathways. The European Union benefits from shared regulatory principles but retains national differences in reimbursement and service delivery. G7 systems generally have stronger clinical infrastructure and pharmacovigilance capabilities, though affordability and care coordination remain relevant. GCC countries often combine well-resourced urban services with a focus on specialist-led care, while NATO members span diverse health systems and preparedness priorities that influence supply resilience and continuity of treatment.

Country Insights: Distinct Health-System Priorities

Australia and Canada prioritize guideline-based care across geographically dispersed populations. Brazil and Mexico must address regional disparities in specialist access and diagnostic follow-up. China and India combine substantial clinical demand with differences between urban and rural services. France, Germany, Italy, Spain, and the United Kingdom operate within established European care frameworks while differing in reimbursement, referral pathways, and prescribing practice. Japan and South Korea emphasize specialist monitoring and structured healthcare delivery. Russia's care environment is shaped by domestic access, procurement, and regional service variation. The United States places strong emphasis on adverse-event monitoring, specialist care, and treatment choice, alongside persistent affordability and access considerations.

Priorities for Leaders: Strengthen Safety, Access, and Continuity

Industry leaders should align product strategy with evidence-based treatment pathways and provide practical tools for thyroid-function monitoring, adverse-event recognition, and adherence support. Partnerships with clinicians, pharmacies, laboratories, and public health systems can improve continuity of care, particularly where specialist access is limited. Digital and AI-enabled services should be introduced with clinical validation, transparent governance, cybersecurity controls, and human review. Supply planning should prioritize quality assurance, regulatory compliance, and resilience across diverse procurement channels. Patient-facing education should use clear language and reinforce the need to seek urgent evaluation for serious warning symptoms.

Research Methodology: Evidence-Led Market Assessment

This executive summary applies a structured review of established clinical practice, medicine-safety principles, healthcare-system characteristics, regulatory considerations, and regional access conditions relevant to antithyroid preparations. The assessment integrates the specified regional, group, and country geographies without using market estimates, market sizing, market shares, forecasts, or company-specific claims. Interpretations are framed as qualitative insights and should be validated against current national guidelines, regulatory communications, pharmacovigilance findings, and local prescribing information before operational use.

Conclusion: Safe, Context-Aware Management Remains Central

The antithyroid preparations landscape is defined by individualized treatment, vigilant safety monitoring, and uneven access to diagnosis and follow-up. Regional and country differences make adaptable care models essential, while artificial intelligence offers useful support for surveillance and workflow prioritization when properly governed. Sustainable progress depends on evidence-based prescribing, reliable diagnostics, patient education, resilient supply, and coordination among clinicians, regulators, health systems, and communities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Antithyroid Preparations Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Carbimazole
  • 7.3. Methimazole
  • 7.4. Propylthiouracil

8. Antithyroid Preparations Market, by Product Form

  • 8.1. Introduction
  • 8.2. Injectables
  • 8.3. Liquids
  • 8.4. Tablets

9. Antithyroid Preparations Market, by Product Type

  • 9.1. Introduction
  • 9.2. Branded
  • 9.3. Generic

10. Antithyroid Preparations Market, by Indication

  • 10.1. Introduction
  • 10.2. Graves Disease
  • 10.3. Toxic Nodular Goiter

11. Antithyroid Preparations Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Home Care
  • 11.4. Hospitals

12. Antithyroid Preparations Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy
  • 12.4. Retail Pharmacy

13. Antithyroid Preparations Market, by Region

  • 13.1. Introduction
  • 13.2. Asia-Pacific
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Europe
  • 13.6. Middle East
  • 13.7. Africa

14. Antithyroid Preparations Market, by Group

  • 14.1. Introduction
  • 14.2. ASEAN
  • 14.3. GCC
  • 14.4. European Union
  • 14.5. BRICS
  • 14.6. G7
  • 14.7. NATO

15. Antithyroid Preparations Market, by Country

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. United Kingdom
  • 15.7. Germany
  • 15.8. France
  • 15.9. Russia
  • 15.10. Italy
  • 15.11. Spain
  • 15.12. China
  • 15.13. India
  • 15.14. Japan
  • 15.15. Australia
  • 15.16. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. Market Concentration Analysis, 2025
    • 16.2.1. Concentration Ratio (CR)
    • 16.2.2. Herfindahl Hirschman Index (HHI)
  • 16.3. Recent Developments & Impact Analysis, 2025
  • 16.4. Product Portfolio Analysis, 2025
  • 16.5. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Amneal Pharmaceuticals LLC
  • 17.3. Aurobindo Pharma Ltd.
  • 17.4. Bayer AG
  • 17.5. Bio-T Ltd.
  • 17.6. Cadila Healthcare Ltd.
  • 17.7. Cipla Limited
  • 17.8. Dr. Reddy's Laboratories Ltd.
  • 17.9. Emcure Pharmaceuticals Ltd.
  • 17.10. Gland Pharma Ltd.
  • 17.11. GlaxoSmithKline plc
  • 17.12. Haffkine Bio-Pharmaceutical Corporation Ltd.
  • 17.13. Intas Pharmaceuticals Ltd.
  • 17.14. Ipca Laboratories Ltd.
  • 17.15. Lannett Company, Inc.
  • 17.16. Lupin Limited
  • 17.17. Merck & Co., Inc.
  • 17.18. Mylan N.V.
  • 17.19. Novartis International AG
  • 17.20. Orion Corporation
  • 17.21. Pfizer Inc.
  • 17.22. Piramal Enterprises Ltd.
  • 17.23. Sanofi S.A.
  • 17.24. Strides Pharma Science Ltd.
  • 17.25. Sun Pharmaceutical Industries Ltd.
  • 17.26. Teva Pharmaceutical Industries Ltd.
  • 17.27. The Procter & Gamble Company
  • 17.28. Torrent Pharmaceuticals Ltd.
  • 17.29. Uni-Sankyo Ltd.
  • 17.30. Wockhardt Ltd.

18. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Antithyroid Preparations Market, Years Considered for the Study
  • FIGURE 2. Global Antithyroid Preparations Market, Research Design
  • FIGURE 3. Global Antithyroid Preparations Market, Research Framework
  • FIGURE 4. Global Antithyroid Preparations Market, Data Triangulation
  • FIGURE 5. Global Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Antithyroid Preparations Market Size, by Drug Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Antithyroid Preparations Market Size, by Drug Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Antithyroid Preparations Market Size, by Product Form, 2025 vs 2032 (%)
  • FIGURE 9. Global Antithyroid Preparations Market Size, by Product Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Antithyroid Preparations Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 11. Global Antithyroid Preparations Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Antithyroid Preparations Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 13. Global Antithyroid Preparations Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Antithyroid Preparations Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Antithyroid Preparations Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Antithyroid Preparations Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 17. Global Antithyroid Preparations Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Antithyroid Preparations Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 19. Global Antithyroid Preparations Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Antithyroid Preparations Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Antithyroid Preparations Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 22. Global Antithyroid Preparations Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Antithyroid Preparations Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Antithyroid Preparations Market Segmentation & Coverage
  • TABLE 2. Global Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 4. Global Carbimazole Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Carbimazole Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Carbimazole Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Methimazole Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Methimazole Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Methimazole Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Propylthiouracil Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Propylthiouracil Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Propylthiouracil Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 14. Global Injectables Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Injectables Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Injectables Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Liquids Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Liquids Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Liquids Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 24. Global Branded Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global Branded Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global Branded Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global Generic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 28. Global Generic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 29. Global Generic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 30. Global Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 31. Global Graves Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Graves Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Graves Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Toxic Nodular Goiter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Toxic Nodular Goiter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Toxic Nodular Goiter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 38. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 48. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 56. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 57. Global Antithyroid Preparations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Asia-Pacific Antithyroid Preparations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Asia-Pacific Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 60. Asia-Pacific Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 61. Asia-Pacific Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 62. Asia-Pacific Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 63. Asia-Pacific Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 64. Asia-Pacific Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 65. North America Antithyroid Preparations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. North America Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 67. North America Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 68. North America Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 69. North America Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 70. North America Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 71. North America Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 72. Latin America Antithyroid Preparations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Latin America Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 74. Latin America Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 75. Latin America Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 76. Latin America Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 77. Latin America Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 78. Latin America Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 79. Europe Antithyroid Preparations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Europe Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 81. Europe Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 82. Europe Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 83. Europe Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 84. Europe Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 85. Europe Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 86. Middle East Antithyroid Preparations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Middle East Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 88. Middle East Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 89. Middle East Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 90. Middle East Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 91. Middle East Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 92. Middle East Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 93. Africa Antithyroid Preparations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 94. Africa Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 95. Africa Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 96. Africa Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 97. Africa Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 98. Africa Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 99. Africa Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 100. Global Antithyroid Preparations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 101. ASEAN Antithyroid Preparations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 102. ASEAN Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 103. ASEAN Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 104. ASEAN Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 105. ASEAN Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 106. ASEAN Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 107. ASEAN Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 108. GCC Antithyroid Preparations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 109. GCC Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 110. GCC Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 111. GCC Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 112. GCC Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 113. GCC Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 114. GCC Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 115. European Union Antithyroid Preparations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 116. European Union Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 117. European Union Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 118. European Union Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 119. European Union Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 120. European Union Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 121. European Union Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 122. BRICS Antithyroid Preparations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 123. BRICS Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 124. BRICS Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 125. BRICS Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 126. BRICS Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 127. BRICS Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 128. BRICS Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 129. G7 Antithyroid Preparations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 130. G7 Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 131. G7 Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 132. G7 Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 133. G7 Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 134. G7 Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 135. G7 Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 136. NATO Antithyroid Preparations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 137. NATO Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 138. NATO Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 139. NATO Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 140. NATO Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 141. NATO Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 142. NATO Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 143. Global Antithyroid Preparations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 144. United States Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 145. United States Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 146. United States Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 147. United States Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 148. United States Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 149. United States Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 150. United States Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 151. Canada Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 152. Canada Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 153. Canada Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 154. Canada Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 155. Canada Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 156. Canada Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 157. Canada Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 158. Mexico Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 159. Mexico Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 160. Mexico Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 161. Mexico Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 162. Mexico Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 163. Mexico Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 164. Mexico Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 165. Brazil Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 166. Brazil Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 167. Brazil Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 168. Brazil Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 169. Brazil Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 170. Brazil Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 171. Brazil Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 172. United Kingdom Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 173. United Kingdom Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 174. United Kingdom Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 175. United Kingdom Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 176. United Kingdom Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 177. United Kingdom Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 178. United Kingdom Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 179. Germany Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 180. Germany Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 181. Germany Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 182. Germany Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 183. Germany Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 184. Germany Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 185. Germany Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 186. France Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 187. France Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 188. France Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 189. France Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 190. France Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 191. France Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 192. France Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 193. Russia Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 194. Russia Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 195. Russia Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 196. Russia Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 197. Russia Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 198. Russia Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 199. Russia Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 200. Italy Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 201. Italy Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 202. Italy Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 203. Italy Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 204. Italy Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 205. Italy Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 206. Italy Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 207. Spain Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 208. Spain Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 209. Spain Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 210. Spain Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 211. Spain Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 212. Spain Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 213. Spain Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 214. China Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 215. China Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 216. China Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 217. China Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 218. China Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 219. China Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 220. China Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 221. India Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 222. India Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 223. India Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 224. India Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 225. India Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 226. India Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 227. India Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 228. Japan Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 229. Japan Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 230. Japan Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 231. Japan Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 232. Japan Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 233. Japan Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 234. Japan Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 235. Australia Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 236. Australia Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 237. Australia Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 238. Australia Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 239. Australia Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 240. Australia Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 241. Australia Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 242. South Korea Antithyroid Preparations Market Size, 2017-2032 (USD Million)
  • TABLE 243. South Korea Antithyroid Preparations Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 244. South Korea Antithyroid Preparations Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 245. South Korea Antithyroid Preparations Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 246. South Korea Antithyroid Preparations Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 247. South Korea Antithyroid Preparations Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 248. South Korea Antithyroid Preparations Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 249. Global Antithyroid Preparations Market Share, by Key Player, 2025
  • TABLE 250. Global Antithyroid Preparations Market, Key Experts